IFM-514

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameIFM-514
Drug Alias NameNLRP3 antagonists (IFM Therapeutics)NLRP3 antagonists (IFM Tre/IFM Therapeutics)NLRP3 antagonists (Novartis)IFM-632IFM-514
ClassificationSmall molecules
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitorsImmunomodulators
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsInflammationMetabolic Dysfunction-Associated Steatotic Liver DiseaseGout
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIFM Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis AgIFM Therapeutics IncIfm Tre
Active IndicationsN/A
Inactive IndicationsInflammationMetabolic Dysfunction-Associated Steatotic Liver DiseaseGout

Other Information

ATC CodeN/A
Related LinksN/A